Actavis announced on May 20 it will acquire specialty pharmaceutical company Warner Chilcott plc in a deal worth an estimated $5 billion.
On May 14, healthcare experts met in London to share and discuss developments in cancer detection, prevention, treatment and maintenance, and how IP protection and management are vital in attracting investment.
At the Ideas Matter roundtable last week LSIPR spoke to Maaike van Velzen, general manager of Philips Group Innovation’s IP and Standards division, about the importance of using IP to promote the company’s vision.
The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics.
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents.
England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea.